VP of Finance, Accounting and Administration

Chief Scientific Officer

CG Oncology announces updated data on BOND-003 Cohort C

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

CG Oncology Continues to Demonstrate Best-In-Disease Durability and Tolerability in Bond-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

J&J wins US FDA approval of Inlexzo for bladder cancer

Senior Scientist, Material Science and Technology

CG Oncology is focused on developing innovative immunotherapies to combat bladder cancer. The MSAT Senior Scientist will execute activities supporting late-stage development and BLA readiness, collaborating on CMC development plans and ensuring compliance with regulatory requirements.

Sign up with Google

Sign in with Google